Does L-Methylfolate Help SSRI-Resistant Depression?

In one of two randomized trials, adding 15 mg a day of l-methylfolate to an ongoing SSRI improved depression outcomes. In the other trial, which started patients at 7.5 mg a day, there was no significant difference between groups. These were two multicenter, double-blind, randomized trials in adult outpatients with major depressive disorder who had a partial response or no response to an SSRI. The trial that used 15 mg a day throughout reported a number needed to treat for response of about six.

L-methylfolate was tested here as an add-on, not as a replacement. Patients stayed on their SSRI at a constant dose, and l-methylfolate or placebo was layered on top. That is the question these trials answer: what happens when you add this compound to an antidepressant that has not fully worked.

What the data show:

15 mg a day was the dose that worked: In the second trial, with 75 patients receiving 15 mg a day during both 30-day periods, adjunctive l-methylfolate was significantly more effective than continued SSRI therapy plus placebo on both primary outcome measures, response rate and degree of change in depression symptom score.
Two secondary measures agreed: In that same trial, two secondary outcome measures of symptom severity also favored adjunctive l-methylfolate.
The first trial was negative: In the first trial, with 148 outpatients, no significant difference in outcomes was observed between the treatment groups.
Number needed to treat of about six: For response, the number needed to treat was approximately six in favor of adjunctive l-methylfolate at 15 mg a day.

Both trials were published in the American Journal of Psychiatry in 2012 and enrolled adults with SSRI-resistant major depressive disorder, meaning a partial response or no response to selective serotonin reuptake inhibitors. Both used a sequential parallel comparison design, splitting a 60-day study into two 30-day periods.

Dr. Kumar’s Take

I read this as a positive signal at 15 mg a day and nothing more than that. The trial that gave 15 mg a day through both periods beat placebo on both of its primary measures. The trial that started people at 7.5 mg a day did not separate from placebo at all. So if I am going to use l-methylfolate as an augmentation strategy, I use the dose that was actually shown to work rather than a lower one.

I want to be honest about the weight of the evidence. The positive result comes from the smaller of the two trials, 75 patients, over 60 days. That is a reasonable basis for a trial of therapy in a patient who is already on an SSRI and stuck, and it is not a basis for calling this a settled first-line move ahead of everything else.

What makes it attractive to me clinically is the risk side. L-methylfolate was well tolerated, with rates of adverse events no different from those reported with placebo. When I am weighing augmentation options for a patient with a partial response, the tolerability profile matters as much as the effect size, and a number needed to treat of about six for response is a respectable return for something this benign.

My practical approach: keep the SSRI dose stable, add 15 mg a day, and reassess. If I change two things at once, I will not know which one helped.

Study Snapshot

The authors ran two multicenter trials using a sequential parallel comparison design. In the first, 148 outpatients with SSRI-resistant major depressive disorder entered a 60-day study divided into two 30-day periods. They were randomly assigned in a 2:3:3 ratio to one of three sequences: l-methylfolate for 60 days at 7.5 mg a day for the first 30 days followed by 15 mg a day for the second 30 days, placebo for 30 days followed by l-methylfolate at 7.5 mg a day for 30 days, or placebo for the full 60 days.

The second trial enrolled 75 patients and used an identical design, except that the l-methylfolate dose was 15 mg a day during both 30-day periods.

SSRI dosages were kept constant throughout both studies. Both trials were randomized, double-blind, and placebo-controlled, and both were conducted across multiple centers.

Results in Real Numbers

In the first trial, no significant difference was observed in outcomes between the treatment groups.

In the second trial, adjunctive l-methylfolate at 15 mg a day showed significantly greater efficacy than continued SSRI therapy plus placebo on both primary outcome measures: response rate and degree of change in depression symptom score. Two secondary outcome measures of symptom severity also favored l-methylfolate.

The number needed to treat for response was approximately six in favor of adjunctive l-methylfolate at 15 mg a day. In plain terms, treating about six patients this way yields one additional responder compared with continuing the SSRI plus placebo.

L-methylfolate was well tolerated, with rates of adverse events no different from those reported with placebo.

Who Benefits Most

The population studied was adults with major depressive disorder who had a partial response or no response to selective serotonin reuptake inhibitors. They were outpatients, and they stayed on their SSRI at a constant dose throughout.

That is the group the authors’ conclusion applies to: patients already on an SSRI who are stuck at partial improvement or no improvement, and who need something added rather than something swapped.

The dose that carried the positive result was 15 mg a day. The trial sequence that began at 7.5 mg a day did not produce a significant difference between groups.

Safety, Limits, and Caveats

Tolerability was the strongest part of this data set. L-methylfolate was well tolerated across both trials, and rates of adverse events were no different from those reported with placebo. The authors’ conclusion describes the strategy as effective, safe, and relatively well tolerated at 15 mg a day.

The limits are real and worth stating plainly. Each study ran 60 days, split into two 30-day periods, so this is short-term data. The positive finding rests on the second trial, the smaller of the two, with 75 patients. The first trial, with 148 outpatients, found no significant difference between treatment groups.

The trials tested augmentation of SSRIs specifically, in patients with a partial response or no response to those drugs. Both used a sequential parallel comparison design rather than a conventional parallel-group design.

I would treat the 15 mg finding as a reason to try this in the right patient, not as proof that it belongs in every regimen.

Practical Takeaways

If you and your clinician are considering l-methylfolate augmentation for depression that has only partially responded to an SSRI, 15 mg a day is the dose that showed benefit in these trials.
Keep the SSRI at a stable dose when adding l-methylfolate. Both trials held SSRI dosages constant, and changing two things at once makes it impossible to tell what helped.
The studies measured outcomes over 60 days, in two 30-day periods. Give the trial of therapy a defined window and then reassess honestly rather than drifting.
Understand that one of the two trials was negative. This is a reasonable option to try, not a guaranteed one.
Discuss it with your own clinician before adding anything to an antidepressant. The safety profile in these trials matched placebo, but the decision belongs in the context of your full medication list.

FAQs

How does l-methylfolate help with depression?

In these trials it was used as an add-on to an SSRI that had not produced a full response. At 15 mg a day, adjunctive l-methylfolate was significantly better than continued SSRI plus placebo on response rate and on degree of change in depression symptom score, with a number needed to treat for response of about six.

What dose of l-methylfolate was tested?

Two doses appear in these studies. The second trial used 15 mg a day throughout both 30-day periods, and that is the trial that showed significant benefit. The first trial used sequences that began at 7.5 mg a day, one escalating to 15 mg a day in the second period, and that trial showed no significant difference between treatment groups.

How long does it take for l-methylfolate to work?

Each study ran 60 days, divided into two 30-day periods, so the benefit reported at 15 mg a day was measured within that window.

Are there side effects from taking l-methylfolate with SSRIs?

L-methylfolate was well tolerated in these trials, with rates of adverse events no different from those reported with placebo. The authors described the strategy as safe and relatively well tolerated at 15 mg a day.

Who should consider l-methylfolate augmentation?

The authors’ conclusion applies to patients with major depressive disorder who have a partial response or no response to SSRIs. That is the group enrolled, and the group in whom 15 mg a day of adjunctive l-methylfolate showed benefit.

Bottom Line

Adjunctive l-methylfolate at 15 mg a day was significantly more effective than continuing an SSRI plus placebo in the second of two randomized trials, with a number needed to treat for response of about six. The first trial, which started patients at 7.5 mg a day, found no significant difference between groups. Tolerability was good, with adverse event rates no different from placebo. For a patient with a partial response or no response to an SSRI, this is a low-risk augmentation strategy worth discussing, with the dose that earned the evidence being 15 mg a day.

Final Study Link

Read the study